Search results for "cardiovascular."

showing 10 items of 8644 documents

An unusual association of left‐sided gastroschisis and persistent right umbilical vein

2018

Key Clinical Message Gastroschisis is a full‐thickness congenital abdominal wall defect usually occurring to the right of the umbilicus. About twenty cases of left‐sided gastroschisis have been reported, without reference to the laterality of the umbilical vein. This first case highlights the importance of considering and reporting this association by the perinatal team.

medicine.medical_specialtyprenatal diagnosisGastroschisisbusiness.industryUmbilicus (mollusc)Abdominal wall defectPrenatal diagnosisGeneral Medicinegastrointestinal malformation030204 cardiovascular system & hematologymedicine.diseaseLeft sidedUmbilical veinRight umbilical veinSurgery03 medical and health sciencesabdominal wall defect0302 clinical medicineClinical Images030220 oncology & carcinogenesisClinical ImageLateralitymedicinebusinessClinical Case Reports
researchProduct

The progression rate of aortic stenosis: key to tailoring the management and potential target for treatment

2021

: Aortic stenosis is the most frequent valvular disease to require intervention in the western world and has always been featured as a progressive disease. The rate of progression can be assessed by carefully performed Doppler echocardiography and can vary greatly between individuals with a profound impact on prognosis. Unfortunately, the determinants of disease progression had been insufficiently studied and remain challenging to define, particularly in the outpatient setting. Multiple factors have been proposed and tested, but at present, there are no proven therapies to slow the course of the stenotic process. Heart valve clinics may be particularly important to define the progression ra…

medicine.medical_specialtyprogression rateaortic stenosis degenerative progression rate valvulopathies030204 cardiovascular system & hematologyDoppler echocardiography03 medical and health sciences0302 clinical medicineValvular diseaseRisk FactorsmedicineHumansdegenerative030212 general & internal medicineHeart valveIntensive care medicinemedicine.diagnostic_testbusiness.industryDisease progressionaortic stenosisGeneral MedicineAortic Valve Stenosismedicine.diseasePrognosisvalvulopathiesEchocardiography DopplerStenosismedicine.anatomical_structureaortic stenosis; degenerative; progression rate; valvulopathiesAortic valve stenosisDisease ProgressionProgression rateCardiology and Cardiovascular MedicinebusinessProgressive disease
researchProduct

Prevention, diagnosis and treatment of venous thromboembolism

2020

Machaj Dominik, Cyboran Katarzyna, Płaczek Alicja, Baran Marlena, Wojnowski Michał. Prevention, diagnosis and treatment of venous thromboembolism. Journal of Education, Health and Sport. 2020;10(6):88-94. eISSN 2391-8306. DOI http://dx.doi.org/10.12775/JEHS.2020.10.06.009 https://apcz.umk.pl/czasopisma/index.php/JEHS/article/view/JEHS.2020.10.06.009 https://zenodo.org/record/3889858 The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019. © The Authors 2020; This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland Ope…

medicine.medical_specialtypulmonary embolismDeep veinvenous thromboembolismLumen (anatomy)Thrombophiliadeep vein thrombosisEducationmedicinemedia_common.cataloged_instancecardiovascular diseasesThrombusEuropean unionVeinmedia_commonbusiness.industryRmedicine.diseaseLThrombosisSurgeryPulmonary embolismmedicine.anatomical_structureGV557-1198.995MedicinebusinessSportsJournal of Education, Health and Sport
researchProduct

Treatment of high- and intermediate-risk pulmonary embolism using the AngioJet percutaneous mechanical thrombectomy system in patients with contraind…

2018

Introduction Intravenous thrombolysis is the treatment of choice in patients presenting with high- and intermediate-risk pulmonary embolism. The role of percutaneous mechanical pulmonary thrombectomy (PMPT) is not fully established, although selected patients can be managed with this method. Aim This open-label single-centre prospective pilot study was aimed at assessing the feasibility of PMPT for the treatment of severe pulmonary embolism in a Polish hospital. We also evaluated the safety and efficacy of such management. Material and methods We managed 7 patients, aged 52.7 ±16.6 years, presenting with high- and intermediate-risk pulmonary embolism (4 patients with class 5 and one patient…

medicine.medical_specialtypulmonary embolismPercutaneousUrologymedicine.medical_treatmentEmbolectomy030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinepulmonary arteryPulmonary thrombectomymedicine.arteryFibrinolysismedicine030212 general & internal medicinethromboembolic diseaseOriginal Paperbusiness.industryGastroenterologyObstetrics and GynecologyThrombolysismedicine.diseaseSurgeryPulmonary embolismmechanical thrombectomy systemPneumoniaPulmonary arterySurgerybusinessVideosurgery and Other Miniinvasive Techniques
researchProduct

Variation of platelet function in clinical phenotypes of acute venous thromboembolism – Results from the GMP‐VTE project

2022

Background The role of platelets in the pathogenesis of venous thromboembolism (VTE) is receiving increasing attention; however, limited information is available on platelet function in the acute phase of the disease. Objective To characterize platelet function according to VTE phenotypes. Patients/Methods In total, 154 subjects (isolated pulmonary embolism [iPE], n = 28; isolated deep vein thrombosis [iDVT], n = 35; DVT+PE, n = 91) were included. In this study platelet function analyzer (PFA)-200, light transmission aggregometry (LTA), thrombin generation (TG) in presence (PRP) and absence (PFP) of platelets and platelet flow cytometry were investigated. LASSO regression was used to select…

medicine.medical_specialtypulmonary embolismPlatelet Function TestsPULMONARY-EMBOLISMplatelet functionDeep veinvenous thromboembolism610 MedizinDETERMINANTSGastroenterologydeep vein thrombosisDISEASEPathogenesischemistry.chemical_compoundPlatelet degranulationRISK-FACTOR610 Medical sciencesInternal medicineHumansMedicinePlateletcardiovascular diseasesPOPULATIONVenous Thrombosisbusiness.industryHematologymedicine.diseaseABSENCEThrombosisPREDICTSPulmonary embolismASPIRINAdenosine diphosphatePhenotypeEpinephrinemedicine.anatomical_structurechemistrythrombin generationVOLUMEbusinessmedicine.drugJournal of Thrombosis and Haemostasis
researchProduct

Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism Internation…

2021

Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of hemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International THrOmbolysis (PEITHO)-3 study (ClinicalTrials.gov Identifier: NCT04430569) is a randomized, placebo-controlled, double-blind, multicenter, multinational trial with long-term follow-up. We will c…

medicine.medical_specialtypulmonary embolismVentricular Dysfunction Rightmedicine.medical_treatment2720 HematologyHemodynamicsHemorrhage610 Medicine & health030204 cardiovascular system & hematologyintermediate-high-risk; prognosis; pulmonary embolism; randomized trial; reduced-dose thrombolysis03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicinerandomized trialHumansThrombolytic TherapyDecompensationStrokeHeparinbusiness.industry10031 Clinic for AngiologyHematologyThrombolysismedicine.diseasereduced-dose thrombolysis3. Good healthPulmonary embolismRegimenTreatment OutcomeBlood pressure030228 respiratory systemTissue Plasminogen ActivatorHeart failureAcute DiseaseCardiologyprognosisintermediate-high-riskbusiness
researchProduct

Are biological drugs effective and safe in older severe asthmatics?

2019

Introduction: The treatment of asthma in older ages follows the recommendations of international guidelines for the management of asthma in younger ages, although older age has always represented an exclusion criterion for eligibility to pharmacological trials. This poses a clinical challenge when deciding whether elderly severe asthmatics are candidates for biological drugs. Areas covered: The current article has a narrative structure to review the current literature on efficacy and safety of novel pharmacological drugs against immunoglobulins and interleukins that mediate and orchestrate the main inflammatory pathways in severe asthma, in order to explore whether older subjects (i.e. >…

medicine.medical_specialtypulmonary eosinophilia/drug therapyeducationImmunoglobulinsmonoclonal030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-asthmatic AgentSeverity of Illness IndexBiological drugs03 medical and health sciences0302 clinical medicineimmune system diseasesInternal medicineSeverity of illnessImmunoglobulinHumansMedicineAnti-Asthmatic AgentPharmacology (medical)Age FactorAnti-Asthmatic AgentsAsthmaAgedRandomized Controlled Trials as TopicBiological ProductsAsthma/drug therapybiologyhumanizedbusiness.industryInterleukinsAge FactorsGeneral MedicineInterleukinmedicine.diseaseAsthmarespiratory tract diseasesantibodie030220 oncology & carcinogenesisMonoclonalPractice Guidelines as Topicbiology.proteinBiological Productanti-asthmatic agents/pharmacologyAntibodybusinessHuman
researchProduct

EMG, Rate of Perceived Exertion, Pain, Tolerability and Possible Adverse Effects of a Knee Extensor Exercise with Progressive Elastic Resistance in P…

2020

In people with haemophilia (PWH), elastic band training is considered an optimal option, even though the literature is scarce. The aim was to evaluate normalized electromyographic amplitude (nEMG), rate of perceived exertion (RPE), pain, tolerability, and possible adverse effects during the knee extension exercise using multiple elastic resistance intensities in PWH. During a single session, 14 severe PWH undergoing prophylactic treatment performed knee extensions without resistance and with different intensity levels of elastic resistance. nEMG was measured for the knee extensors and participants rated their RPE, tolerability and pain intensity after each condition. Patients had to report …

medicine.medical_specialtyquadricepslcsh:MedicinePerceived exertion030204 cardiovascular system & hematologyHaemophiliaArticle03 medical and health sciences0302 clinical medicinemedicineIn patientAdverse effectexercise therapymuscle activityKnee extensorsbusiness.industrylcsh:Rhaemophilic arthropathy030229 sport sciencesGeneral Medicinemedicine.diseaseIntensity (physics)Knee painTolerabilityPhysical therapymedicine.symptombusinessstrength
researchProduct

Safety, Fear and Neuromuscular Responses after a Resisted Knee Extension Performed to Failure in Patients with Severe Haemophilia

2021

BACKGROUND: low-moderate intensity strength training to failure increases strength and muscle hypertrophy in healthy people. However, no study assessed the safety and neuromuscular response of training to failure in people with severe haemophilia (PWH). The purpose of the study was to analyse neuromuscular responses, fear of movement, and possible adverse effects in PWH, after knee extensions to failure.METHODS: twelve severe PWH in prophylactic treatment performed knee extensions until failure at an intensity of five on the Borg CR10 scale. Normalised values of amplitude (nRMS) and neuromuscular fatigue were determined using surface electromyography for the rectus femoris, vastus medialis,…

medicine.medical_specialtyquadricepsneuromuscular fatigueVastus medialisStrength trainingkinesiophobiaElectromyography030204 cardiovascular system & hematologyTraining to failureHaemophiliaArticleMuscle hypertrophy03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationEMGArthropathymedicineAdverse effectmedicine.diagnostic_testbusiness.industryR030229 sport sciencesGeneral Medicinemedicine.diseaseMedicineresistance trainingbusinessarthropathy
researchProduct

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy

2015

Context: The therapeutic strategy in intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy (IT) is not well defined. Most patients are usually retreated by Bacillus Calmette-Guerin (BCG). Aims: To evaluate the efficacy of intravesical chemotherapy (ICH) given at recurrence after the first cycle of ICH in IR-NMIBC recurring 6 months or later. Settings and Design: Retrospective analysis of the efficacy of ICH given after previous IT. Materials and Methods: The clinical files of IR-NMIBC patients recurring later than 6 months after transurethral resection (TUR) and IT and retreated by IT were reviewed. The patients should be at intermediate risk…

medicine.medical_specialtyrecurrenceUrologyContext (language use)intermediate risklcsh:RC870-923Settore MED/24 - UrologiaCytologyintravesical chemotherapyAdjuvant therapyMedicinecardiovascular diseasesBacillus Calmette-GuerinBladder cancermedicine.diagnostic_testbusiness.industryProportional hazards modelCystoscopylcsh:Diseases of the genitourinary system. Urologymedicine.diseaseSurgerynervous system diseasesBacillus Calmette-Guerin intermediate risk intravesical chemotherapy non muscle invasive bladder cancer recurrenceMann–Whitney U testnon muscle invasive bladder cancerOriginal ArticlebusinessIntravesical chemotherapyUrology Annals
researchProduct